Taysha Gene Therapies Inc

NASDAQ:TSHA 4:00:00 PM EDT

2.41

-0.04 (-1.63%)

: $2.44 +0.03 (+1.25%)

Market Cap (Intraday)	450.73M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$2.48 Million
Adjusted EPS	-$0.11

See more estimates

10-Day MA	$2.64
50-Day MA	$2.53
200-Day MA	$2.05

See more pivots

Taysha Gene Therapies Inc Stock, NASDAQ:TSHA

3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247

United States of America

Phone: +1.214.612.0000

Number of Employees: 52

http://www.tayshagtx.com

Description

Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.